Marjolein Geurts
Brain Tumour Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marjolein Geurts as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:48 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06809322 · Vorasidenib Maintenance for IDH Mutant AstrocytomaEuropean Organisation for Research and Treatment of Cancer - EORTC · recruiting · IDH-mutant Grade 2 or 3 Astrocytoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:48 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.Ann Intern Med · 2012271 citationsRCR 9.8
- Surgical decompression for space-occupying cerebral infarction: outcomes at 3 years in the randomized HAMLET trial.Stroke · 201370 citationsRCR 3.0
- Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study.Ann Rheum Dis · 201054 citationsRCR 1.9
- COOLIST (Cooling for Ischemic Stroke Trial): A Multicenter, Open, Randomized, Phase II, Clinical Trial.Stroke · 201741 citationsRCR 1.7
- Implications of a clinical medication review and a pharmaceutical care plan of polypharmacy patients with a cardiovascular disorder.Int J Clin Pharm · 201638 citationsRCR 2.4